Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Wix.com Ltd. has launched a major share repurchase program as its stock trades near multi-year lows. While analysts have trimmed price targets, many maintain bullish ratings, citing significant upside potential and a more resilient outlook for SaaS companies in the face of AI disruption.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
While an IRS extension grants an extra six months to file, experts caution that the April 15 payment deadline is non-negotiable. We break down the process, benefits, and common pitfalls for the millions considering this option.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Cotton futures extended losses on Friday, pressured by a stronger U.S. dollar and a significant year-over-year decline in export commitments. The market's focus remains on demand concerns as key metrics lag behind historical averages.
Corn futures extended losses on Friday, pressured by a strengthening U.S. dollar and weaker crude oil prices. Despite robust export sales data running ahead of historical pace, front-month contracts fell 5 to 5.5 cents, pushing the national average cash price lower.
While consumer staples are traditionally seen as safe havens, recent underperformance against the broader market has spotlighted companies with weakening fundamentals. We examine three household names where valuation and growth concerns suggest caution is warranted.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Profitability alone doesn't guarantee a winning stock. We examine three firms—Chewy, RH, and Proto Labs—that are in the black but face significant headwinds that may limit their future returns, prompting investors to look elsewhere for growth.
Saks Global is closing the majority of its Saks OFF 5TH discount locations, including the final two in Massachusetts, amid a corporate restructuring following its recent bankruptcy filing.
In remarks that now appear pointed, Fed Chair Jerome Powell robustly defended the central bank's personnel and economic frameworks just days before former Governor Kevin Warsh, a vocal critic, was nominated to potentially succeed him.
Cullen/Frost Bankers (NYSE: CFR) reported fourth-quarter revenue in line with expectations but delivered a significant earnings beat, driven by its aggressive branch network expansion in Texas and robust commercial lending. Management expressed confidence in sustained loan growth and improving margins for the coming year.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
The Federal Reserve's decision to hold interest rates steady signals a strategic pause, not an end to its easing cycle. We break down the immediate and future impacts on everything from credit cards to the housing market.
Dover Corporation topped revenue and profit forecasts for the fourth quarter, fueled by robust order growth in climate tech and retail segments. However, shares dipped as management issued a guarded outlook for the coming year, citing input cost pressures and macroeconomic uncertainty.
Valley National Bancorp (VLY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by robust core deposit growth and disciplined balance sheet management. The regional bank's leadership pointed to strategic tech investments and commercial loan demand as key pillars for its 2025 outlook.
The floral and gift e-commerce giant 1-800-FLOWERS reported a 9.5% year-over-year revenue decline to $702.2 million for its fiscal fourth quarter, aligning with Wall Street's subdued expectations. However, disciplined cost management fueled a significant earnings beat, with non-GAAP EPS of $1.20 surging 39.5% above estimates.
While lofty price targets can signal opportunity, a closer look reveals that not all consensus forecasts are created equal. We examine one company poised to deliver and two where investor caution may be warranted.